Role of P53 and Bcl-2 in Advanced Rectal Carcinomas Treated with Adjuvant Therapy

Summary Rectal adenocarcinomas is usually associated to a poorer outcome than colon cancers. In this study we analyzed the impact on overall survival of p53 and Bcl-2, evaluated by immunohistochemical techniques, in 126 advanced rectal cancer patients submitted to 5 fluorouracil based adjuvant therapy. Shorter overall survival was observed in patients bearing p53 positive and Bcl-2 negative tumors, although in multivariate analysis only p53 emerged as independent predictor of a worse outcome. These results seem to indicate that, in stage III-IV rectal cancer, p53 alterations may identify high risk patients to be enrolled in more aggressive and/or innovative adjuvant/neoadjuvant treatments.

[1]  P. Coucke,et al.  Predictive factors in locally advanced rectal cancer treated with preoperative hyperfractionated and accelerated radiotherapy. , 2003, Human pathology.

[2]  C. Vagianos,et al.  bcl-2/bax Ratio as a Predictive Marker for Therapeutic Response to Radiotherapy in Patients With Rectal Cancer , 2001, Applied immunohistochemistry & molecular morphology : AIMM.

[3]  I. D'Agnano,et al.  p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. , 2001, American journal of clinical pathology.

[4]  B. Iacopetta,et al.  p53 Gene Mutation, Microsatellite Instability and Adjuvant Chemotherapy: Impact on Survival of 388 Patients with Dukes’ C Colon Carcinoma , 2000, Oncology.

[5]  I. D'Agnano,et al.  Evaluation of multiple bio‐pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl‐2 , 1999, International journal of cancer.

[6]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[7]  G. Chinnadurai,et al.  Unmasking of a proliferation-restraining activity of the anti-apoptosis protein EBV BHRF1. , 1996, Oncogene.

[8]  K. Kinzler,et al.  Paradoxical inhibition of solid tumor cell growth by bcl2. , 1994, Cancer research.

[9]  H. Wieand,et al.  Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Paradiso,et al.  Colorectal Clinical Experimental Oncology Laboratory and 2 , 2022 .